hpv16 e7 (49-57) peptide

The HPV16 E7 (49-57) peptide is a nine-amino acid sequence (RAHYNIVTF) derived from the E7 oncoprotein of Human Papillomavirus type 16. It is a well-characterized immunodominant epitope restricted by the murine MHC class I molecule H-2Db. This peptide is extensively used in preclinical research, particularly in the TC-1 tumor model, to evaluate the efficacy of therapeutic HPV vaccines, T-cell based therapies, and immunomodulatory agents. By stimulating CD8+ cytotoxic T lymphocyte (CTL) responses against E7-expressing cells, the peptide serves as a critical tool for developing strategies to treat HPV-associated malignancies, such as cervical cancer and oropharyngeal squamous cell carcinoma. In clinical contexts, similar E7-derived peptides are incorporated into synthetic long peptide (SLP) vaccines or DNA vaccine platforms to induce systemic anti-tumor immunity. The specific notation 'E7HHH49-57' likely refers to a modified version of this epitope, potentially containing a triple-histidine tag or representing a typographical variant of the standard H-2Db-restricted sequence.

Other names

HPV16 E7 49-57 peptideHPV-16 E7 49-57 peptideHPV 16 E7 49-57 peptideH-2Db-restricted HPV16 E7 peptideH2Db-restricted HPV16 E7 peptideH 2Db-restricted HPV16 E7 peptideE7HHH49-57 peptideE-7HHH49-57 peptideE 7HHH49-57 peptide